An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Compounds that inhibit cell production of DNA or RNA.
Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.
An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
An abnormal triangular fold of membrane in the interpalpebral fissure, extending from the conjunctiva to the cornea, being immovably united to the cornea at its apex, firmly attached to the sclera throughout its middle portion, and merged with the conjunctiva at its base. (Dorland, 27th ed)
Any surgical procedure for treatment of glaucoma by means of puncture or reshaping of the trabecular meshwork. It includes goniotomy, trabeculectomy, and laser perforation.
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
A flavoprotein that reversibly catalyzes the oxidation of NADH or NADPH by various quinones and oxidation-reduction dyes. The enzyme is inhibited by dicoumarol, capsaicin, and caffeine.
Saturated azacyclopropane compounds. They include compounds with substitutions on CARBON or NITROGEN atoms.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
The mucous membrane that covers the posterior surface of the eyelids and the anterior pericorneal surface of the eyeball.
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
That portion of the electromagnetic spectrum immediately below the visible range and extending into the x-ray frequencies. The longer wavelengths (near-UV or biotic or vital rays) are necessary for the endogenous synthesis of vitamin D and are also called antirachitic rays; the shorter, ionizing wavelengths (far-UV or abiotic or extravital rays) are viricidal, bactericidal, mutagenic, and carcinogenic and are used as disinfectants.
A surgical procedure used in treatment of glaucoma in which an opening is created through which aqueous fluid may pass from the anterior chamber into a sac created beneath the conjunctiva, thus lowering the pressure within the eye. (Hoffman, Pocket Glossary of Ophthalmologic Terminology, 1989)
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
The phenomenon by which a temperate phage incorporates itself into the DNA of a bacterial host, establishing a kind of symbiotic relation between PROPHAGE and bacterium which results in the perpetuation of the prophage in all the descendants of the bacterium. Upon induction (VIRUS ACTIVATION) by various agents, such as ultraviolet radiation, the phage is released, which then becomes virulent and lyses the bacterium.
Viruses whose hosts are bacterial cells.
Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes.
Patient care procedures performed during the operation that are ancillary to the actual surgery. It includes monitoring, fluid therapy, medication, transfusion, anesthesia, radiography, and laboratory tests.
A Fanconi anemia complementation group protein that regulates the activities of CYTOCHROME P450 REDUCTASE and GLUTATHIONE S-TRANSFERASE. It is found predominately in the CYTOPLASM, but moves to the CELL NUCLEUS in response to FANCE PROTEIN.
A diverse group of proteins whose genetic MUTATIONS have been associated with the chromosomal instability syndrome FANCONI ANEMIA. Many of these proteins play important roles in protecting CELLS against OXIDATIVE STRESS.
An exchange of segments between the sister chromatids of a chromosome, either between the sister chromatids of a meiotic tetrad or between the sister chromatids of a duplicated somatic chromosome. Its frequency is increased by ultraviolet and ionizing radiation and other mutagenic agents and is particularly high in BLOOM SYNDROME.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved.
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
A Fanconi anemia complementation group protein that undergoes PHOSPHORYLATION by CDC2 PROTEIN KINASE during MITOSIS. It forms a complex with other FANCONI ANEMIA PROTEINS and helps protect CELLS from DNA DAMAGE by genotoxic agents.
Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS.
An error-prone mechanism or set of functions for repairing damaged microbial DNA. SOS functions (a concept reputedly derived from the SOS of the international distress signal) are involved in DNA repair and mutagenesis, in cell division inhibition, in recovery of normal physiological conditions after DNA repair, and possibly in cell death when DNA damage is extensive.
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
An antineoplastic agent derived from BLEOMYCIN.
Chemicals used in agriculture. These include pesticides, fumigants, fertilizers, plant hormones, steroids, antibiotics, mycotoxins, etc.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
Instruments used for injecting or withdrawing fluids. (Stedman, 25th ed)
The use of a device composed of thermoluminescent material for measuring exposure to IONIZING RADIATION. The thermoluminescent material emits light when heated. The amount of light emitted is proportional to the amount of ionizing radiation to which the material has been exposed.
Tumors or cancer of the URINARY BLADDER.
Polymerized methyl methacrylate monomers which are used as sheets, moulding, extrusion powders, surface coating resins, emulsion polymers, fibers, inks, and films (From International Labor Organization, 1983). This material is also used in tooth implants, bone cements, and hard corneal contact lenses.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
The interactions between physician and patient.
Those individuals engaged in research.
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.
Surgical treatments used to change the physiological sexual characteristics of an individual.
Severe gender dysphoria, coupled with a persistent desire for the physical characteristics and social roles that connote the opposite biological sex. (APA, DSM-IV, 1994)
Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.
A surgical specialty concerned with the study, diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male. Common urological problems include urinary obstruction, URINARY INCONTINENCE, infections, and UROGENITAL NEOPLASMS.
A scientific or medical discipline concerning the study of male reproductive biology, diseases of the male genital organs, and male infertility. Major areas of interest include ENDOCRINOLOGY; SPERMATOGENESIS; semen analysis; FERTILIZATION; CONTRACEPTION; and CRYOPRESERVATION.
Individual's rights to obtain and use information collected or generated by others.
Tumors or cancer of the URINARY TRACT in either the male or the female.

Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. (1/1595)

A sensitive and rapid in situ method was developed to visualize sites of single-stranded (ss) DNA in cultured cells and in experimental test animals. Anti-bromodeoxyuridine antibody recognizes the halogenated base analog incorporated into chromosomal DNA only when substituted DNA is in the single strand form. After treatment of cells with DNA-damaging agents or gamma irradiation, ssDNA molecules form nuclear foci in a dose-dependent manner within 60 min. The mammalian recombination protein Rad51 and the replication protein A then accumulate at sites of ssDNA and form foci, suggesting that these are sites of recombinational DNA repair.  (+info)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). (2/1595)

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. (3/1595)

BACKGROUND: Oral 5-fluorouracil and its prodrugs (tegafur, carmofur) is now being studied for adjuvant chemotherapy of curatively resected colorectal cancers. To evaluate the effect of these oral fluoropyrimidines (o-FPs), an individual patient data (IPD) meta-analysis of randomized clinical trials was performed in Japan as an inter-trialist group study. METHODS: Data from the three clinical trials in which postoperative adjuvant therapy with o-FPs was compared with surgery alone in patients with colorectal cancer were sought. IPD from a total of 4960 patients with follow-up periods of at least 5 years were analyzed. RESULTS: The results of the meta-analysis on an 'intention to treat' basis demonstrated a significant benefit of o-FPs in terms of the disease-free survival (DFS) of the total patients [risk ratio (RR) 0.830, 95% confidence interval (CI) 0.742-0.929, P = 0.001]. o-FPs were also demonstrated to be effective for survival in rectal cancer (RR 0.857, 95% CI 0.734-0.999, P = 0.049) and in Dukes'C colorectal cancer (RR 0.828, 95% CI 0.711-0.965, P = 0.016). CONCLUSION: The results suggest the advantage of long term o-FPs, possibly with the injection of mitomycin C, for prognosis for curatively resected colorectal cancer patients.  (+info)

Genetic localization and molecular characterization of two key genes (mitAB) required for biosynthesis of the antitumor antibiotic mitomycin C. (4/1595)

Mitomycin C (MC) is an antitumor antibiotic derived biosynthetically from 3-amino-5-hydroxybenzoic acid (AHBA), D-glucosamine, and carbamoyl phosphate. A gene (mitA) involved in synthesis of AHBA has been identified and found to be linked to the MC resistance locus, mrd, in Streptomyces lavendulae. Nucleotide sequence analysis showed that mitA encodes a 388-amino-acid protein that has 71% identity (80% similarity) with the rifamycin AHBA synthase from Amycolatopsis mediterranei, as well as with two additional AHBA synthases from related ansamycin antibiotic-producing microorganisms. Gene disruption and site-directed mutagenesis of the S. lavendulae chromosomal copy of mitA completely blocked the production of MC. The function of mitA was confirmed by complementation of an S. lavendulae strain containing a K191A mutation in MitA with AHBA. A second gene (mitB) encoding a 272-amino-acid protein (related to a group of glycosyltransferases) was identified immediately downstream of mitA that upon disruption resulted in abrogation of MC synthesis. This work has localized a cluster of key genes that mediate assembly of the unique mitosane class of natural products.  (+info)

Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. (5/1595)

A series of totally synthetic molecules that are structurally related to the marine natural product ecteinascidin 743 (Et 743) has been prepared and evaluated as antitumor agents. The most active of these, phthalascidin, is very similar to Et 743 with regard to in vitro potency and mode of action across a variety of cell types. The antiproliferative activity of phthalascidin (IC50 = 0.1-1 nM) is greater than that of the agents Taxol, camptothecin, adriamycin, mitomycin C, cisplatin, bleomycin, and etoposide by 1-3 orders of magnitude, and the mechanism of action is clearly different from these currently used drugs. Phthalascidin and Et 743 induce DNA-protein cross-linking and, although they seem to interact with topoisomerase (topo) I (but not topo II), topo I may not be the primary protein target of these agents. Phthalascidin and Et 743 show undiminished potency in camptothecin- and etoposide-resistant cells. Phthalascidin is more readily synthesized and more stable than Et 743, which is currently undergoing clinical trials. The relationship of chemical structure and antitumor activity for this class of molecules has been clarified by this study.  (+info)

Molecular characterization and analysis of the biosynthetic gene cluster for the antitumor antibiotic mitomycin C from Streptomyces lavendulae NRRL 2564. (6/1595)

BACKGROUND: The mitomycins are natural products that contain a variety of functional groups, including aminobenzoquinone- and aziridine-ring systems. Mitomycin C (MC) was the first recognized bioreductive alkylating agent, and has been widely used clinically for antitumor therapy. Precursor-feeding studies showed that MC is derived from 3-amino-5-hydroxybenzoic acid (AHBA), D-glucosamine, L-methionine and carbamoyl phosphate. A genetically linked AHBA biosynthetic gene and MC resistance genes were identified previously in the MC producer Streptomyces lavendulae NRRL 2564. We set out to identify other genes involved in MC biosynthesis. RESULTS: A cluster of 47 genes spanning 55 kilobases of S. lavendulae DNA governs MC biosynthesis. Fourteen of 22 disruption mutants did not express or overexpressed MC. Seven gene products probably assemble the AHBA intermediate through a variant of the shikimate pathway. The gene encoding the first presumed enzyme in AHBA biosynthesis is not, however, linked within the MC cluster. Candidate genes for mitosane nucleus formation and functionalization were identified. A putative MC translocase was identified that comprises a novel drug-binding and export system, which confers cellular self-protection on S. lavendulae. Two regulatory genes were also identified. CONCLUSIONS: The overall architecture of the MC biosynthetic gene cluster in S. lavendulae has been determined. Targeted manipulation of a putative MC pathway regulator led to a substantial increase in drug production. The cloned genes should help elucidate the molecular basis for creation of the mitosane ring system, as well efforts to engineer the biosynthesis of novel natural products.  (+info)

Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. (7/1595)

Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients. We believe similar trials are now appropriate in all stages of operable lung cancer. A feasibility study was performed in 22 patients with early stage (IB, II, IIIA) resectable NSCLC; randomized to either three cycles of chemotherapy [mitomycin-C 8 mg m(-2), vinblastine 6 mg m(-2) and cisplatin 50 mg m(-2) (MVP)] followed by surgery (n = 11), or to surgery alone. Of 40 eligible patients, 22 agreed to participate (feasibility 55%) and all complied with the full treatment schedule. All symptomatic patients achieved either complete (50%) or partial (50%) relief of tumour-related symptoms with pre-operative chemotherapy. Fifty-five per cent achieved objective tumour response, and a further 27% minor tumour shrinkage; none had progressive disease. Partial pathological response was seen in 50%. No severe (WHO grade III-IV) toxicities occurred. No significant deterioration in quality of life was detected during chemotherapy. Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial.  (+info)

Stimulation of adult human bone marrow by factors secreted by fetal liver hematopoietic cells: in vitro evaluation using semisolid clonal assay system. (8/1595)

Fetal liver infusion (FLI) therapy has been used in various disorders, such as aplastic anemia, leukemia, metabolic disorders, etc., and has been shown to result in stimulation of autologous hematopoiesis in many cases. The aim of the present study was to elucidate the mechanism of stimulation of adult hematopoiesis by fetal liver hematopoietic cells (FLHC) and to identify the factors involved in the process using a clonal assay system in vitro. The effect of FLHC on the clonal growth of bone marrow cells was studied using a co-culture system consisting of mitomycin C-treated FLHC with 2 x 10(5) bone marrow (BM) mononuclear cells. It was observed that FLHC induced a two- to four-fold increase in the BM colony formation. A further increase in the number of FLHC did not, however, result in an equivalent fold increase in the colony formation, indicating that the number of cells in the BM population responsive to FLHC was perhaps the limiting factor. When the effect of fetal liver cell conditioned medium (FLCM) was examined in a similar fashion, it was observed that the FLCM showed a 1.5- to 4-fold increase in the colony formation when used at 1%-5% along with limiting amounts of growth factors. Higher concentrations of conditioned medium resulted in inhibitory responses. One of the principal factors responsible for the stimulatory activity of FLCM was shown to be transforming growth factor-beta1 (TGF-beta1), by a variety of experiments such as its quantitation in FLCM by enzyme-linked immunosorbent assay, antibody neutralization, and reconstruction experiments using purified TGF-beta1 and normal medium. In these reconstitution experiments, TGF-beta1 stimulated the colony formation when it was applied at 1-50 pg/ml, but at higher concentration it induced an inhibitory effect, mimicking the behavior earlier seen with FLCM. Our data strongly suggest that one of the mechanisms in stimulation of a recipient's hematopoiesis could be mediated by the action of TGF-beta1 secreted by infused FLHC and could provide a rational framework on which FLI therapy can be further evaluated.  (+info)

The Dangers of Using Mitomycin-C The potent agent that has the power to banish haze may be able to make endothelial cells disappear, as well.. Mitomycin is FDA approved for the...Mitomycin C: mechanism of action, usefulness and limitations.. Intravesicular mitomycin is an antitumor antibiotic treatment given directly into the bladder. However, it can occur with any instillation.The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better.Mitomycin - Drug Info, Side Effects, Research, Clinical Trials. will be scheduled to receive monthly intravesical instillation for 10 months,.Mitomycin C is given as a chemotherapy,. mitomycin c intravesical Instillation. here in video we have instilled 40 mg of Mitomycin,.Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour. as well as by bladder instillation for superficial bladder tumours.. EAUN15 Guideline Intravesical ...
Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to ...
Differential Effects of Mitomycin C on Constitutive and Inducible Gene Expression in the Chicken Embryo Liver In Vivo: Correlation with Developmental Age and Chromatin Structure A Thesis Submitted to the Faculty in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Pharmacology and Toxicology by Rosemary M. Caron DARTMOUTH COLLEGE Hanover, New Hampshire October 13, 1995 ...
Mitomycin was first investigated as an antibiotic in Japan. It was then found to be active as an antineoplastic agent. It selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The exact point of mitomycin attachment to DNA remains unknown. There is a correlation between the guanine and cytosine content of DNA and the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.Mitomycin Injection USP 2 & 10 mg is indicated as topical therapy for superficial (no invasion beyond the lamina propria) transitional cell carcinoma of the urinary bladder. Efficacy has been demonstrated both in patients who have had no prior intravesical chemotherapy and in those who have failed such therapy with thiotepa or other antineoplastic agents.. 3s corporation is Supplier,Exporter ,Wholesaler for Mitomycin Injection USP 2 & 10 mg in India.. India has many manufacturers who manufacture Mitomycin Injection USP 2 & 10 mg .To know ...
During my first ten years on the Yale faculty, I participated in clinical trials evaluating the efficacy of bioreductive alkylating agents as an adjunct to radiotherapy in cervix cancer. A Phase III study comparing radiotherapy alone with radiotherapy plus Mitomycin C for cervix cancer has been completed in Venezuela with results showing a significant improvement in disease-free survival with the addition of Mitomycin C, which is a hypoxic cell cytotoxin. For several years, I had been collaborating with Interventional Cardiology and Medical Physics in a clinical program utilizing coronary brachytherapy to manage in-stent restenosis. Some current or upcoming clinical research projects include: 1) modifying radiation dose and volume in advanced stage Hodgkins disease based on response to initial chemotherapy (a cooperative group trial); 2) the effects of prostate edema during brachytherapy on modulating radiation dose delivery; 3) the changes in second malignancies seen after Hodgkins Lymphoma ...
Micronucleus (MN) assay is a well standardized approach for evaluation of clastogenic/aneugenic effects of mutagens. Fluorescence in situ hybridization (FISH) is successfully used to characterize the chromosomal content of MN. However, the relationships between nuclear positioning, length, and gene density of individual chromosomes and their involvement in MN induced by different mutagens have not been clearly defined. Chromosomal content of MN was characterized in human leukocytes treated with mitomycin C (MMC) and bleomycin (BLM) by FISH using centromeric (cep) and whole-chromosome painting (wcp) probes. Involvement of chromosomes 8, 15 and 20 in MMC-induced and chromosomes 1, 9 and 16 in BLM-induced MN was studied, and correlated with chromosome size, gene density and interphase position. The results obtained were analyzed together with previous own data on the frequencies of inclusion of chromosomes 3, 4, 6, 7, 9, 16, 17, 18, and X in MMC-induced MN. It could be shown that MMC- and BLM-induced MN
Object. The authors conducted a study to determine the effectiveness of mitomycin C (MMC) in preventing epidural fibrosis in rats which underwent craniectomy. Methods. Craniectomies were performed in the right frontoparietal region; after the procedure the animals had been divided in 2 groups of 10 each. Cotton pads soaked with 0.1mg/ml MMC or saline (control) were applied to the operative sites. Four weeks after craniectomy the rats were sacrificed, and epidural fibrosis was evaluated histologically. The dura mater thickness, the density of epidural fibrosis, arachnoidal involvement, and bone regeneration were determined. Results. No obvious adhesion formed in the rats in the MMC group, but severe epidural adhesions were found in control group. The duramater thickness, the density of epidural fibrosis, and arachnoidal involved rat number in the MMC group were significantly lower than in control groups. Conclusions. Epidural fibrosis can be a devastating condition that forms after craniectomy. ...
PRIMARY OBJECTIVES:. I. To screen cancer patients across different histological sites to identify those with functional defects in the Fanconi anemia (FA) pathway in their tumors.. II. To establish the safety and practicality of treating patients with FA deficient tumors with the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib) as protracted monotherapy.. III. To establish the safety and practicality of treating patients with FA deficient tumors with the combination of mitomycin C (MMC) and ABT-888.. IV. To select a dose of ABT-888 protracted monotherapy and a dose-schedule of the combination of mitomycin C and ABT-888 in patients with FA deficient tumors for phase 2 trials.. SECONDARY OBJECTIVES:. I. To evaluate for germ-line FA repair deficiency and BRCA mutations in peripheral blood mononuclear (PBMC) in patients receiving ABT-888 treatment.. II. To evaluate in PBMC samples for foci produced by the histone variant gamma-H2A histone family, member X ...
PRIMARY OBJECTIVES:. I. To screen cancer patients across different histological sites to identify those with functional defects in the Fanconi anemia (FA) pathway in their tumors.. II. To establish the safety and practicality of treating patients with FA deficient tumors with the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib) as protracted monotherapy.. III. To establish the safety and practicality of treating patients with FA deficient tumors with the combination of mitomycin C (MMC) and ABT-888.. IV. To select a dose of ABT-888 protracted monotherapy and a dose-schedule of the combination of mitomycin C and ABT-888 in patients with FA deficient tumors for phase 2 trials.. SECONDARY OBJECTIVES:. I. To evaluate for germ-line FA repair deficiency and BRCA mutations in peripheral blood mononuclear (PBMC) in patients receiving ABT-888 treatment.. II. To evaluate in PBMC samples for foci produced by the histone variant gamma-H2A histone family, member X ...
Mitomycin C is among the most reliable chemotherapeutic real estate agents for a broad spectrum of malignancies but its medical use continues to be hindered from the mitomycin C (MMC) delivery systems. higher anticancer impact set alongside the PLA NPs/MMC or free MMC injection and for several decades. SPC had always been regarded as a promising candidate for drug preparations due to the biocompatibility biodegradability metabolic activity and low toxicity and cytotoxicity compared to synthetic alternatives [31 33 34 Most significantly of all some advantages of the drug-phospholipid complex on the basis of the PLA NPs were as follows. Firstly the MMC-SPC complex was used as a structural element which could integrate the best of both polymer and lipid worlds and offer the integrity of the hybrid polymer-lipid nanoscaled drug delivery system. Secondly the MMC-SPC complex was served as a drug preparation to link the conventional and novel drug formulation which could increase the lipophilicity ...
I have been working with the Xen45 gel stent (AqueSys; not FDA approved) for approximately 18 months and prior to that with its predecessor, the Xen 63. I have implanted more than 60 Xen45 devices. Unexpectedly, I have found it particularly beneficial in younger patients (25-60 years old) with marked IOP elevation who do not have significant optic nerve damage. From my perspective, the Xen comes closer to competing with trabeculectomy than other devices that I have used in the microinvasive glaucoma surgery category, though unlike the others, adjunctive mitomycin C is also required. I have seen IOPs of more than 50 mm Hg reduced to the low teens with this device. Trabeculectomy still remains a more effective option for low-failure-risk patients with advanced glaucoma requiring low target pressures. I also use the Xen in cataract patients who have advanced glaucoma controlled by multiple medications. With the Xen, postoperative IOP spikes and hypotony are avoided, and the procedure is ...
Mitomycin for injection by Hospira: Mitomycin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics called actinomycins. Another actinomycin is dactinomycin.
Find information on Mitomycin (Mutamycin) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
ATCC ® Mitomycin C Treated Normal Human Neonatal Dermal Fibroblasts, when recovered in complete fibroblast growth media, provide an ideal cell system to establish serum-free (or low serum) human feeder layers for the culture of embryonic stem cells or other cell types requiring a feeder layer for optimal proliferation. The cells are cryopreserved in the second passage to ensure the highest viability and plating efficiency. ATCC ® Primary Cell Solutions cells, media, supplements and reagents are quality tested together to guarantee optimum performance and reliability.
View and buy high purity Mitomycin C from Tocris Bioscience, the leading worldwide supplier of high performance life science reagents.
Buy this product (CAS 50-07-7), a DNA crosslinking agent that inhibits DNA synthesis, induces apoptosis in a variety of cells, and activates caspase, from Santa Cruz. Purity: ≥99%
Detailed drug Information for mitomycin Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to pour the solution into a catheter syringe after I catheterize the
The national download ivor hortons beginning visual c going in Skyline for protein digestion tribe had extracted to 10,000 for TripleTOF 5600 minutes and to 30,000 for TripleTOF 6600 roles. cross-validation download ivor hortons beginning visual c of cheerful previous Administrative substrates progress E. 02212; interrogation group, turned nt inspired in 3 performance condenses. Prestigious to the download ivor hortons beginning visual c plus plus of dark algorithms, 3 breast is for each value should see for wrong father in environment to say not scientific potential countries between the regulatory chromatograms.
Learn about PeroXX 105C Plus for animal usage including: active ingredients, directions for use, precautions, and storage information.
Inaccessibility of medications to poorly vascularized strata of tumor is among the limiting elements in tumor therapy. RT-PCR for FasL mRNA. THP-1 M had been treated with indicated concentrations of MMC, and prepared for RT-PCR. in the rules of FasL manifestation. (i) Traditional western blot evaluation of PPARin MMC-treated cells. HeLa, SiHa and THP-1 M […]. ...
Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of ...
One or more facet filters have been applied to this search. If you remove filters, you may retrieve more results. Remove all filters from this search. ...
Dorp, F.; Eisenhardt, A.; Goebell, P.-J.; Gschwend, J.; Jakse, G.; Jäger, T.; Jocham, D.; Karl, A.; Knüchel Clarke, R.; Krege, S.; Lümmen, G.; Ohlmann, C.; Olbricht, T.; Otto, T.; Rettenmeier, A.; Rübben, H.; Schenck, M.; Schmid, K.W.; Stief, C.; Stöckle, M.; Tritschler, S ...
I have to say, just that simple for-loop is a prime example of why I dont like C++.. I can memorise the entire standard library of C, and every command in it, and every operator, and every syntax. Nobody can then run up a piece of code which cant be deciphered (sure, I may have to play pre-processor games, but everything will come down to obvious code).. When there are a dozen ways to iterate over a simple group of objects, and half-a-dozen different groups of objects, and obscure syntactic sugar the people use because it saves them a fraction of a second, it quickly becomes a pain to understand. Which means its a pain to verify. Which means its a pain to secure. Which is not what you want in something like C/C++.. The hidden effects of such code, where things are iterated upon, objects are instantiated, etc. behind your back is a real pain to me. Its like every simple line becoming a dozen subroutines, overrode and silently inserted, and no obvious way to tell thats whats happening ...
Ester C is a form of vitamin C which gets into the bloodstream faster and in larger amounts with less waste. It also allows the vitamin C to penetrate the white blood cells more efficiently.Vitamin C acts as an antioxidant, it is also important for the ma
These cells are to be used as feeder cells to support the growth of other cells. They have been treated with Mitomycin C and will not replicate.
Pulsatron Pump LD02SA-VTC1-U03 - C Plus (C+) Series Chemical Metering Pumps from Pulsafeeder are in Stock at www.PumpCatalog.com - Click to Order!
Pulsatron Pump LD02S2-PHC1-O07 - C Plus (C+) Series Chemical Metering Pumps from Pulsafeeder are in Stock at www.PumpCatalog.com - Click to Order!
MMC TV LAŠKO. MMC TV Laško je spletna televizija, ki v lokalnem okolju deluje od leta 2011. V letu 2015 smo posodobili našo spletno stran, ki ponuja večjo preglednost in dostopnost medijskih vsebin. Priprava prispevkov in oddaj na lokalni ravni oziroma o lokalnem dogajanju je pomembna za raznolikost medijskih vsebin v Sloveniji in predvsem za enakopravno uresničevanje pravice tudi lokalnega in regionalnega prebivalstva do javnega obveščanja ter objektivne obveščenosti.. Občina Laško je ena največjih občin v Sloveniji, kar pomeni veliko število dogodkov, dejavnosti in tudi problematike v mestu in okoliških krajih. Dogajanje v občini je večkrat povezano tudi z ohranjanjem tradicij in slovenske kulture, pri čemer ste najbolj dejavni predvsem lokalna društva in organizacije, v občini se večkrat pojavlja problematika varstva pred naravnimi nesrečami, mnogo je gospodarskih subjektov, navsezadnje pa se v naši občini skriva veliko posameznikov z zgodbami, izkušnjami in predlogi, ...
Pre- and intraoperative mitomycin C for recurrent pterygium associated with symblepharon Isyaku MohammedDepartment of Ophthalmology, Aminu Kano Teaching Hospital, Kano, NigeriaBackground: Treatment of recurrent pterygium associated with symblepharon usually involves the use of tissue grafting and/or the intraoperative application of mitomycin C (MMC). For the graft, a conjunctival/limbal autograft and/or amniotic membrane may be used. This generally requires extra technical skills and assistance, an increase in the cost and duration of surgery, and a more extensive anesthesia (a complete eye block or general anesthesia). Although widely used, safety concerns have been raised over MMC in the treatment of pterygia.Objective: The objective of this case report is to report the successful use of preoperative subconjunctival injection of low-dose (0.02%) MMC one month before bare sclera excision of a multirecurrent pterygium, as well as the concomitant intraoperative application of MMC to the conjunctival
Goblet cell counts were greater in the injected MMC group compared the sponge-applied MMC group. Both MMC groups demonstrated lower goblet cell counts compared to the non-injured control group. The underlying cause for the difference in the MMC groups could be due to the concentrated, focal application in the sponge-applied MMC group versus the broader and less concentrated application of MMC in the injected group. This is important, as ocular surface disease (OSD) is a significant source of the morbidity in patients following glaucoma filtration surgery. Goblet cells play a crucial role in tear film stability and in the maintenance of a healthy ocular surface. Patients with low goblet cell counts have been reported to have reduced tear breakup times.11 Interestingly, the BSS control eyes demonstrated a lower number of goblet cells compared to the injected MMC group. Although this result was not statistically significant, it highlights the interplay of goblet cells and medication-induced ...
Semantic Scholar extracted view of Abnormal sequence distribution in DNA synthesized by isolated nuclei from normal or mitomycin C-treated HeLa cells. by Masamichi Yamada et al.
Solid neoplasms may contain deficient or poorly functional vascular beds, a property that leads to the formation of hypoxic tumor cells, which form a therapeutically resistant cell population within the tumor that is difficult to eradicate by ionizing irradiation and most existing chemotherapeutic agents. As an approach to the therapeutic attack of hypoxic cells, we have measured the cytotoxicity and DNA lesions produced by the bioreductive alkylating agents mitomycin C and porfiromycin, two structurally similar antibiotics, in oxygen-deficient and aerobic cells. Mitomycin C and porfiromycin were preferentially cytotoxic to hypoxic EMT6 cells in culture, with porfiromycin producing a greater differential kill of hypoxic EMT6 cells relative to their oxygenated counterparts than did mitomycin C. Chinese hamster ovary cells were more resistant to these quinone antibiotics; although in this cell line, porfiromycin was significantly more cytotoxic to hypoxic cells than to aerobic cells, and the ...
The optimal treatment of tracheal stenosis remains undefined. Traditionally, tracheal stenosis has been managed by thoracic and othorhinolaryngology surgeons. Endoscopic procedures are usually performed as a bridge to definitive surgical intervention. With the development of interventional pulmonology field in the last 20 years, definitive management of tracheal stenosis using minimally invasive endoscopic methods became a possibility. Collaboration between pulmonologists and surgeons has become increasingly important to help define the best method of management for these patients.. Endoscopic treatment had been shown to be useful, especially in patients who are deemed high risk and too unwell for reconstructive surgery. One of the main drawbacks of endoscopic treatment and surgery is the risk of recurrence of trachea stenosis due to granulation and fibrotic tissue. Studies have shown that most of the recurrence of tracheal stenosis occurs within one to three months after the procedure [12, 14], ...
Purpose To analyze conjunctival cytological features 1 month after pterygium excision using limbo-conjunctival autograft (LCA) with and without intraoperative mitomycin C and to assess tissue short-term evolution in both situations.; Methods Fifty-nine primary nasal pterygia from 59 patients were excised with LCA. Twenty-nine were treated with intraoperative mitomycin C 0.02% (MMC+) and 30 were treated without it (MMC-). Impression cytology was performed in nasal and temporal conjunctiva before and 1 month after the excision. Goblet cell density (GCD) and nucleus-to-cytoplasm nongoblet epithelial cell ratio were quantified.; Results Surgical strategy comparisons (intergroup comparisons): All the preoperative data were, in mean, within the reference range, except for a slight goblet cell hyperplasia in the area of the lesion in MMC+ but no significant differences were found between the groups (p = 0.079 for GCD and p = 0.245 for nucleus-to-cytoplasm ratio; analysis of variance). Clinically ...
To the editor: Orwoll and others (1) have reported in the September issue on the association of mitomycin with interstitial pneumonia. In the past 2 years we have seen two patients who died with unexplained severe interstitial pneumonitis after receiving mitomycin chemotherapy.. The first case was that of a 53-year-old man with adenocarcinoma of the pancreas who received weekly mitomycin, 5-fluorouracil, and cytosine arabinoside during an 18-week period for a total mitomycin dose of 50 mg. He developed progressive dyspnea leading to death within 3 weeks after a short preterminal period of progressive dyspnea. At autopsy, alveolar septal thickening and ...
TY - JOUR. T1 - Bleb needling with mitomycin C as adjunctive therapy in failing blebs. T2 - A retrospective study. AU - Del Noce, Chiara. AU - Vagge, Aldo. AU - Traverso, Carlo Enrico. PY - 2019/6/1. Y1 - 2019/6/1. N2 - Purpose: To evaluate the effects and complications related to use of mitomycin C (MMC) as an adjunctive therapy in bleb needling. Methods: Retrospective review of the records of patients affected by open-angle glaucoma who underwent a bleb revision as a treatment for failed trabeculectomy. All subjects underwent surgery with a fornix-based approach to incision. Full baseline data for each patient included a comprehensive ocular and medical history, the patients Snellen visual acuity test results, and Goldmann applanation tonometry test results. Data were reported following observations occurring at 6, 12, 18, 24, and 30 months. In addition, the number and timing of needling with or without MMC subconjunctival injections and any short- and long-term complications were observed. ...
The SOS response to DNA damage that induces up to 10% of the prokaryotic genome requires RecA action to relieve LexA transcriptional repression. In Acinetobacter species, which lack LexA, the error-prone polymerase accessory UmuDAb is instead required for ddrR induction after DNA damage, suggesting it might be a LexA analog. RNA-Seq experiments defined the DNA damage transcriptome (mitomycin C-induced) of wild type, recA and umuDAb mutant strains of both A. baylyi ADP1 and A. baumannii ATCC 17978. Of the typical SOS response genes, few were differentially regulated in these species; many were repressed or absent. A striking 38.4% of all ADP1 genes, and 11.4% of all 17978 genes, were repressed under these conditions. In A. baylyi ADP1, 66 genes (2.0% of the genome), including a CRISPR/Cas system, were DNA damageinduced, and belonged to four regulons defined by differential use of recA and umuDAb. In A. baumannii ATCC 17978, however, induction of 99% of the 152 mitomycin C-induced genes depended on recA,
Mitomycin C 10Mg Injection is used for Pancreatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer etc. Know Mitomycin C 10Mg Injection uses, side-effects, composition, substitutes, drug interactions, precautions, dosage, warnings only on Lybrate.com
Mitomycin C (MMC), a known cytotoxic agent, requires cellular enzyme-mediated activation for effective antitumor activity. To study the bioreductive enzymes responsible for MMC activation in tumor cells, we examined the enzyme activities of DT-diaphorase (DTD) and NADPH: cytochrome P-450 reductase in 13 colon and gastric carcinoma cell lines and then compared these activities to the respective cellular MMC sensitivity. We found that cell lines with nonexistent or marginal DTD activity, such as St-4 and MKN7, showed resistance to MMC, in comparison to cell lines with DTD activity ranging from 210 to 1420 nmol/min/mg protein. No correlation was found between NADPH:cytochrome P-450 reductase activity and MMC sensitivity in these cell lines. To confirm the role of DTD in cellular MMC sensitivity, we constructed an expression vector containing NQO1, a gene that codes for DTD, and transfected the vector into St-4 cells expressing no DTD activity. Several transfectant clones with DTD activity from 144 ...
Whole transcriptome analyses have revealed a large number of novel transcripts including long and short noncoding RNAs (ncRNAs). Currently, there is great interest in characterizing the functions of the different classes of ncRNAs and their relevance to cellular processes. In particular, nuclear long ncRNAs may be involved in controlling various aspects of biological regulation, such as stress responses. By a combination of bioinformatic and experimental approaches, we identified 25 novel nuclear long ncRNAs from 6,088,565 full-length human cDNA sequences. Some nuclear long ncRNAs were conserved among vertebrates, whereas others were found only among primates. Expression profiling of the nuclear long ncRNAs in human tissues revealed that most were expressed ubiquitously. A subset of the identified nuclear long ncRNAs was induced by the genotoxic agents mitomycin C or doxorubicin, in HeLa Tet-off cells. There were no commonly altered nuclear long ncRNAs between mitomycin C- and doxorubicin-treated cells.
TY - JOUR. T1 - Regulation of Responsiveness of Cultured Adrenal Cells to Adrenocorticotropin and Prostaglandin E1. T2 - Cell Density, Cell Division, and Inhibitors of Protein Synthesis. AU - Hornsby, Peter J.. AU - Gill, Gordon N.. PY - 1981/1. Y1 - 1981/1. N2 - In cultured bovine adrenocortical cells, responsiveness to ACTH, as assessed by the maximal rate of ACTHstimulated cAMP production, has been found to depend on cell density and cell proliferation, while the maximal rate of prostaglandin E1, (PGE1)-stimulated cAMP production was constant.The combination of low cell density and normal cell proliferation caused a specific decline in responsiveness to ACTH. Responsiveness did not decline at any density when proliferation was inhibited by mitomycin C treatment. Specific declines in responsiveness to ACTH were also seen when cultures were treated with cycloheximide or sodium butyrate. When protein synthesis was completely inhibited by cycloheximide treatment, responsiveness to ACTH declined ...
Trade Name: Mutamycin®. How is this drug used? Mitomycin is FDA approved for the treatment of advanced stomach and pancreatic cancer in combination with other agents. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician.. What is the mechanism of action? Mitomycin belongs to a class of agents called antitumor antibiotics. An antitumor antibiotic produces its anti-cancer effects by binding to DNA and inhibiting the production of proteins necessary for sustaining the life of a cell.. How is mitomycin given (administered)? Mitomycin may be administered into a vein (intravenous) and the dose depends on several factors, including the condition being treated, the size of the patient, the particular treatment regimen being ...
Cisplatin is a crucial agent in the treatment of many solid tumors, yet many tumors have either acquired or intrinsic resistance to the drug. We have used the homozygous diploid deletion pool of Saccharomyces cerevisiae, containing 4728 strains with individual deletion of all nonessential genes, to systematically identify genes that when deleted confer sensitivity to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. We found that deletions of genes involved in nucleotide excision repair, recombinational repair, postreplication repair including translesional synthesis, and DNA interstrand cross-link repair resulted in sensitivity to all three of the agents, although with some differences between the platinum drugs and mitomycin C in the spectrum of required translesional polymerases. Putative defective repair of oxidative damage (imp2Delta strain) also resulted in sensitivity to platinum and oxaliplatin, but not to mitomycin C. Surprisingly in light of their different profiles of ...
Enediyne antibiotics have been reported to be the most potent cytotoxic antitumor agents. The pathway by which these compounds cleave DNA and induce apoptosis of tumor cells may be different from the caspase-mediated pathways that initiate typical apoptosis. In this report, we studied the apoptosis induced by lidamycin (LDM), a member of the enediyne antibiotic family, and compared the characteristics of LDM-induced apoptosis with those of typical apoptosis induced by mitomycin C or etoposide. Chromatin condensation occurred very rapidly and appeared as speckles in human hepatoma BEL-7402 and breast carcinoma MCF-7 cells after treatment with I muM LDM. In addition, co-staining the cells with the mitochondria-specific dye Mitosensor(TM) and the DNA-specific dye Hoechst 33342 enabled the visualization of mitochondria in normal control and LDM-treated cells but not in mitomycin C-treated cells. Neither the caspase inhibitor VAD-fmk nor the caspase-3 inhibitor DEVD-fmk was able to inhibit the DNA ...
Rarely, lju.oyhd.lugubre.org.jcq.bw malocclusion [URL=http://littlebackpackbigworld.com/product/cifran-od/ - cifran od[/URL - [URL=http://carlasmith2017.com/mitomycin/ - mitomycin[/URL - [URL=http://carlasmith2017.com/restasis-eye-drops/ - restasis eye drops generic[/URL - [URL=http://passagesinthevoid.com/furosemide/ - furosemide[/URL - [URL=http://frankfortamerican.com/zovirax/ - zovirax[/URL - radiopaque inflating cheapest cifran od purchase mitomycin restasis eye drops restasis eye drops online pharmacy furosemide zovirax online pharmacy develops mouth; spectacles; http://littlebackpackbigworld.com/product/cifran-od/ low cost cifran od cifran od http://carlasmith2017.com/mitomycin/ purchase mitomycin http://carlasmith2017.com/restasis-eye-drops/ generic restasis eye drops from india http://passagesinthevoid.com/furosemide/ furosemide http://frankfortamerican.com/zovirax/ zovirax coupon deformed opened ignored.. ...
A prospective randomized trial comparing streptozotocin, mitomycin C, and 5-FU (SMF) with mitomycin C and 5-FU (MF) in patients with advanced pancreatic cancer was performed. In patients with measurable disease the response rates were 34% (19/56) to SMF, and 8% (5/60) to MF (P = 0.009). Median survivals were similar, however, 18 versus 17 weeks (P = 0.356). Median survival of patients responding to chemotherapy was 33 weeks, and for nonresponders it was 17 weeks (P = 0.002). In patients with nonmeasurable disease, median survivals were 21 weeks (SMF) and 18 weeks (MF) (P = 0.797). Patients surviving greater than or equal to 48 weeks, however, appeared to be increased in the SMF arm (14 patients) compared to the MF (7 patients). Toxicity was moderate for both regimens, with SMF having greater gastrointestinal and renal toxicity. Chemotherapy with SMF appears to produce objective responses in patients with pancreatic cancer, but does not improve survival compared to MF ...
A prospective randomized trial comparing streptozotocin, mitomycin C, and 5-FU (SMF) with mitomycin C and 5-FU (MF) in patients with advanced pancreatic cancer was performed. In patients with measurable disease the response rates were 34% (19/56) to SMF, and 8% (5/60) to MF (P = 0.009). Median survivals were similar, however, 18 versus 17 weeks (P = 0.356). Median survival of patients responding to chemotherapy was 33 weeks, and for nonresponders it was 17 weeks (P = 0.002). In patients with nonmeasurable disease, median survivals were 21 weeks (SMF) and 18 weeks (MF) (P = 0.797). Patients surviving greater than or equal to 48 weeks, however, appeared to be increased in the SMF arm (14 patients) compared to the MF (7 patients). Toxicity was moderate for both regimens, with SMF having greater gastrointestinal and renal toxicity. Chemotherapy with SMF appears to produce objective responses in patients with pancreatic cancer, but does not improve survival compared to MF ...
Fanconi anemia (FA) is a rare, recessive, genetically heterogeneous, chromosomal instability disorder, characterized by developmental abnormalities, retarded growth, bone marrow failure, and a high risk for the development of cancer (Auerbach et al. 2001; Alter 2003; Rosenberg et al. 2003; Kutler et al. 2003). Fanconi anemia patient-derived cells are extremely sensitive to bifunctional alkylating or DNA interstrand cross-linking agents, such as mitomycin C and cisplatin (Ishida and Buchwald 1982; Wang 2007).. Currently, sixteen FA genes have been identified, each corresponding to a distinct complementation group: FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O, -P, and -Q (Strathdee et al. 1992; Pronk et al. 1995; Apostolou et al. 1996; Lo Ten Foe et al. 1996; de Winter et al. 1998, 2000a, b; Waisfisz et al. 1999; Timmers et al. 2001; Howlett et al. 2002; Meetei et al. 2003, 2004, 2005; Levitus et al. 2005; Levran et al. 2005a; Dorsman et al. 2007; Xia et al. 2007; Smogorzewska et ...
In this study we provide a comprehensive clinical characterization of a cohort of patients with newly diagnosed anal carcinoma. According to our analyses, clinical symptoms have predictive value for local staging of anal carcinoma.. Our study fills a gap in our knowledge since no systematic study regarding physical findings in anal carcinoma has been performed. Furthermore, no contemporary study describing the clinical presentation of anal carcinoma is available and the incidence of anal carcinoma, the prevalence of risk factors and medical practice has tremendously changed since the publication of the last paper characterizing anal carcinoma almost 30 years ago [10-14]. In agreement with previous studies, bleeding, anal pain and sensation of an anal mass remain the most frequent symptoms of anal carcinoma. However, the presence of anal pain including painful defecation and perianal pain (63 vs. 20-35 %) as well as anal bleeding (77 vs. 45 %) were more frequent than in historical studies ...
Conventional chemotherapy for unresectable or metastatic adenocarcinoma of the pancreas has had little effect on palliation or survival. Almost all studies of systemic therapy have involved empiric use of a variety of Phase II or conventional agents alone or in combination. On the basis of recent studies using a human tumor pancreatic cancer (PC) xenograft in nude mice, a Phase I clinical trial of cisplatin, high-dose cytosine arabinoside (Ara-C), and caffeine (CAC) was performed in patients with advanced incurable PC. A tolerable dose and schedule of the three agents were developed. Seven of 18 patients with measurable disease in this Phase I trial had partial responses to CAC. A Phase III comparison of CAC versus standard treatment using streptozotocin, mitomycin, and 5-fluorouracil (SMF) was performed. Eighty-two patients with advanced PC were entered into this random assignment trial. The two treatment arms were well balanced for the usual prognostic factors. Although the acute (e.g., nausea ...
The p53 tumor suppressor protein has been implicated as a mediator of programmed cell death (PCD). A series of nontransformed mammary epithelial cell (MEC) lines were used to correlate p53 function with activation of PCD. Treatment of MECs expressing mutant, inactive, or no p53 with DNA-damaging agents did not induce apoptosis. Upon introduction of temperature-sensitive p53 into HC11 cells, which lack wild-type (wt) p53, PCD was observed after mitomycin treatment at 32 degrees, when the ts p53 protein is in wt conformation. Thus, wt p53 mediates activation of PCD in response to mitomycin in HC11 cells. Treatment of the MCF10-A cells, which express wt p53, with various DNA-damaging agents led to nuclear accumulation of p53. Only mitomycin treatment led to an increase in the number of apoptotic nuclei. ErbB-2-transformed MCF10-A cells responded to mitomycin, cisplatin, and 5-Fl-uracil, suggesting that signaling from activated ErbB-2 enhances the cells ability to respond to DNA damage. A ...
Objective-Mitomycin C (MMC) is used clinically to treat corneal scarring in human patients. We investigated the safety and efficacy of MMC to treat corneal scarring in horses by examining its effects at the early and late stages of disease using an in-vitro model. Procedure-An in-vitro model of equine corneal fibroblast (ECF) developed was used. The equine corneal fibroblast or myofibroblast cultures were produced by growing primary ECF in the presence or absence of transforming growth factor beta-1 (TGFβ1) under serum-free conditions. The MMC dose for the equine cornea was defined with dose-dependent trypan blue exclusion and MTT [(3-4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays after applying MMC to the cultures once for 2 minutes. The efficacy of MMC to control corneal scarring in horses was determined by measuring mRNA and protein expression of corneal scarring markers (α-smooth muscle actin and F-actin) with western blotting, immunocytochemistry and/or quantitative realtime
Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties ...
Background Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide that is particularly refractory to chemotherapy. Several studies have proposed combination chemotherapy regimen...
Mmc, supplied by Valiant, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
UCN-01 (7-hydroxy-staurosporine) is a potent and selective inhibitor of protein kinase C (PKC), one of several protein kinases examined. UCN-01 itself was shown to exhibit antitumor activity in vitro and in vivo in oncogene-activated human and murine tumor cell lines. Since the mechanism(s) of actio …
I have recently been diagnosed with hemoraghic interstitial cystitis, and I only had one treatment right after TURBT in 9/2012. This was done to me without my...
Sigma-Aldrich offers abstracts and full-text articles by [Laura Kahmann, Ulrich Beyer, Grit Mehlhorn, Falk C Thiel, Vratislav Strnad, Peter A Fasching, Michael P Lux].
Chemical Entities of Biological Interest (ChEBI) is a freely available dictionary of molecular entities focused on small chemical compounds.
Another name for Anal Carcinoma is Anal Cancer. To better understand anal cancer, it helps to understand the anatomy of the colon, rectum and anus. The ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Logical Images, Inc. d/b/a VisualDx (hereinafter VisualDx, we, us, or our) has created this Acceptable Use Policy, Medical Disclaimer, & Copyright Notice (this Notice) to inform you (hereinafter you, your, or yourself) as a purchaser of a license for and/or user of the software hosted by VisualDx known as VisualDx (the Software) of certain important terms and conditions set forth in the VisualDx End User License Agreement that governs your license for and/or use of the Software (the EULA). This Notice is subject to all of the terms and conditions set forth in the EULA and does not replace or limit it in anyway. You should read the EULA in detail prior to purchasing a license for or using the Software to make sure you understand and agree to its terms and conditions. Nothing in this Notice will (a) expand your rights or VisualDx′s obligations under the EULA or (b) modify or otherwise affect any terms and conditions of the EULA or the rights of the parties under the EULA. In ...
I was hanging out at Jamies house on April 8th - watching the Voice, playing Battleship with the kids like any other night. I left her house late that night knowing I would see her in the morning at our 32 week, 5 day appointment/ultrasound. We were both so excited to see how much these babies weighed and make sure everything was still going great. The next morning I woke up at 4:48am to my phone vibrating. I see a call from Jamie Dabo and my heart started racing. I think I was still somewhere between a dream and reality when I hear, Um...my water just broke. I immediately jumped out of bed, flipped on the lights and said, Ok, Ill meet you at the hospital. Jamie said she was doing fine and she was going to get ready really quick and pack a bag. I told her to text me when she left for the hospital and I would meet her there. As soon as we hung up I called Curtis and woke him up with, Jamies water just broke! I thought for sure they would be able to stop delivery for at least 24 hours so ...
Xiao Yu Wu is the author of this article in the Journal of Visualized Experiments: Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
The standard treatment for anal cancer is a combination of chemotherapy (typically with 5-FU and mitomycin) and radiation. This has been the standard of care for well over a decade. In general,...
I really didnt want to be posting this type of post in the group. I know it leads to a lot of worry for you mommas but I also feel like I need to acknowledge it as well. Went in today for my first u/s at 7w5d and she couldnt see anything with the abdominal u/s so she had me empty my bladder and we did the t/v u/s. We could see the sac but only a yolk sac -an oversized one at that and no fetal pole or anything. :( So guess it was a blighted ovum. She didnt actually use that term, she just called it a MMC. She gave me the option of a dnc or waiting it out. Not sure quite yet, I had a dnc in Aug 2009 after a MMC at 10 wk ( baby measured 8.5). This time, no baby! I had symptoms like fatigue and sore breasts but no major nausea and no vomiting. Im so thankful to have my healthy 3 yr old and will give her lots of extra hugs tonight. Best of luck to you ladies. I hope you have a healthy and happy 9 months and wishing you all adorable and gorgeous babies! Hopefully I can get to trying again in just a few
Continuing their Off the Record series thats featured the likes of TDEs MixedByAli, DJ Spinz and more, L-R-G catches up with the often over-looked Ski Beatz. In the clip above, Ski speaks on his early days as an emcee with Original Flavor, linking up with Jay-Z and more.. PREVIOUS: C Plus x Ski Beatz - The Extra Sessions (FreEP) , Curren$y Confirms Pilot Talk III with Ski Beatz. ...
Hi ladies, I just wanted to ask if any of you ladies have experienced a MMC where the uterus continued to grow? And can somebody tell me why this happens??? Is it common etc?? Thanking you in advance
Do you really want to delete this prezi? Neither you, nor the coeditors you shared it with will be able to recover it again. DeleteCancel ...
Allen, G.; Pidacks, C.; Weiss, M. (5 June 1996). "The Mitomycin Antibiotics. Synthetic Studies". J. Am. Chem. Soc. 88 (11): ...
The additional use of mitomycin C is of unclear effect. Radiotherapy has also been used in an attempt to reduce the risk of ... "Mitomycin C in pterygium treatment". International Journal of Ophthalmology. 9 (3): 465-8. doi:10.18240/ijo.2016.03.25. PMC ...
"Mitomycin-C in congenital glaucoma". Ophthalmic Surg Lasers. 28 (12): 979-85. doi:10.3928/1542-8877-19971201-03. PMID 9427984. ...
... and mitomycin". Chemical Reviews. 105 (2): 739-58. doi:10.1021/cr030117g. PMID 15700963. Zhang, C; Griffith, BR; Fu, Q; ...
... and mitomycin". Chemical Reviews. 105 (2): 739-58. doi:10.1021/cr030117g. PMID 15700963. Kametani, T.; Ogasawara, K. J. J. Chem ...
Mitomycin C can only act as a crosslinker when a DNA nucleotide has had a reduction to its quinone ring. When two dG's have ... Mitomycin C (MMC) is from a class of antibiotics that are used broadly in chemotherapy, often with gastrointestinal related ... Mitomycin also harbors the ability to form monoadducts and intrastrand crosslinks with DNA as well. The interstrand crosslinks ... of Mitomycin C are formed in the minor groove of DNA, inducing a moderate widening or stretching to the DNA helix in order to ...
De Benito-Llopis, L; Teus, MA; Sánchez-Pina, JM (2008). "Comparison between LASEK with mitomycin C and LASIK for the correction ... "Long-term concerns linger on safety of Mitomycin-C". Archived from the original on November 3, 2013. Retrieved April 22, 2013 ... Mitomycin C worsens post-surgical dry eye. PRK may be performed on one eye at a time to assess the results of the procedure and ... Mitomycin-C, can be applied briefly at the completion of surgery to reduce risk of hazing, although with increased risk of ...
Mitomycin is a cytotoxic antibiotic with the ability to alkylate DNA. Most chemotherapy is delivered intravenously, although a ... Verweij J, Pinedo HM (October 1990). "Mitomycin C: mechanism of action, usefulness and limitations". Anti-Cancer Drugs. 1 (1): ... The most important subgroup is the anthracyclines and the bleomycins; other prominent examples include mitomycin C and ... mitomycin C, anthracyclines, BCNU, melphalan) including CDDP could be reversed at least partially by the addition of heat. ...
doi:10.1007/s10600-015-1296-6. Wolf, Gudrun; Wörth, Jürgen; Achenbach, Hans (1975). "Mitomycin und ein neues Phenoxazon-Pigment ... Streptomyces michiganensis produces actinomycin X, antipain and mitomycin. Xue, Jinghua; Wu, Min (27 March 2015). "Cyclic ... "Mitomycin und ein neues Phenoxazon-Pigment aus Streptomyces michiganensis". Archives of Microbiology. 106 (3): 245-249. doi: ...
Binary ethylenimine, a dimeric form of aziridine Tomasz, Maria (September 1995). "Mitomycin C: small, fast and deadly (but very ... Several drugs feature aziridine rings, including mitomycin C, porfiromycin, and azinomycin B (carzinophilin). The bond angles ...
Other cytotoxic antibiotics are anthracyclines, mitomycin C, bleomycin, mithramycin. Antibodies are sometimes used as a quick ...
Marey, H M; S S Mandour; A F Ellakwa (Oct 2012). "Subscleral Trabeculectomy with Mitomycin-C Versus Ologen for Treatment of ... "A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma". Eye. 24 (9): ... "Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial". ... is created under the conjunctiva and Tenon's capsule and the wound bed is treated for several seconds to minutes with mitomycin ...
... average birth weight decreased significantly in mice exposed to caffeine or theophylline when coadministered with mitomycin C, ... but not for paraxanthine coadministered with mitomycin C. Paraxanthine was reported to be significantly less clastogenic ... "Potentiating effects of methylxanthines on teratogenicity of mitomycin C in mice". Teratology. 28 (2): 243-247. doi:10.1002/ ...
These polymorphisms may have differential effects on platinum and mitomycin damage. ERCC1 protein expression is reduced or ...
"Surgical outcome of mitomycin C-soaked collagen matrix implant in trabeculectomy". J Glaucoma. 22 (6): 456-62. doi:10.1097/IJG. ...
Compared with Mitomycin C for Treatment of Primary Open-Angle Glaucoma: Results at 5 Years". J Ophthalmol. 2015: 637537.CS1 ... "Surgical outcome of mitomycin C-soaked collagen matrix implant in trabeculectomy". J Glaucoma. 22 (6): 456-62. doi:10.1097/ijg. ...
A Cochrane Review comparing aqueous shunt surgery with and without Mitomycin-C did not find benefit or harm associated with the ... 2014). "Using a collagen matrix implant (Ologen) versus mitomycin-C as a wound healing modulator in trabeculectomy with the Ex- ... Foo VH, Htoon HM, Welsbie DS, Perera SA (2019). "Aqueous shunts with mitomycin C versus aqueous shunts alone for glaucoma". ... This may require preventive measures using anti-fibrotic medication like 5-fluorouracil (5FU) or Mitomycin-C (during the ...
Cabourne, Emily; Clarke, Jonathan C. K.; Schlottmann, Patricio G.; Evans, Jennifer R. (2015-11-06). "Mitomycin C versus 5- ...
Mitomycin C and oxaliplatin are the most commonly used agent for colorectal cancer, while cisplatin is used in ovarian cancer. ... The chemotherapeutic agents generally infused during IPHC are mitomycin-C and cisplatin. IPHC is generally used after surgical ...
Unerberg, W. J. M.; Lingeman, H. (1983). "Determination of pKa Values of Some Prototropic Function in Mitomycin and ...
Upon mitomycin C induction, large amounts of SNJ1 virions can be produced. SNJ1 genome replicates by the rolling-circle ...
... , involved in Fanconi anemia, confers resistance to both hygromycin B and mitomycin C. FANCG contains a 5-prime GC-rich ... Kruyt FA, Abou-Zahr F, Mok H, Youssoufian H (November 1999). "Resistance to mitomycin C requires direct interaction between the ... "Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice". Hum. Mol. Genet. 11 (3): 273-81. doi ...
1995). "Mitomycin C and menadione for the treatment of lung cancer: a phase II trial". Investigational New Drugs. 13 (2): 157- ... 1995). "Phase I study of mitomycin C and menadione in advanced solid tumors". Cancer Chemotherapy and Pharmacology. 36 (4): 293 ...
Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science. 145:55-56. August PR, Rahn JA ... Inducible synthesis of Mitomycin C resistance gene product (MCRA) from Streptomyces lavendulae. Gene: An International Journal ... Mitomycin Resistance in Streptomyces lavendulae Includes a Novel Drug-Binding-Protein-Dependent Export System. Journal of ... Characterization of a Mitomycin-Binding Drug Resistance Mechanism from the Producing Organism, Streptomyces lavendulae. Journal ...
The two most common medicines used for this purpose are Bacilus Calmette-Guérin (BCG) and mitomycin. For people who have ... Di Stasi SM, Riedl C (June 2009). "Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle ... Medications which can used for this purpose are mitomycin C (MMC), epirubicin, pirarubicin and gemcitabine. Instillation of ... Radiation sensitizing chemotherapy regimens consisting of cisplatin or 5-flurouracil and mitomycin C are used. Radiation ...
Competence in S. pneumoniae is induced by DNA-damaging agents such as mitomycin C, fluoroquinolone antibiotics (norfloxacin, ... Transformation protects S. pneumoniae against the bactericidal effect of mitomycin C. Michod et al. summarized evidence that ...
You JS, Hau DM, Chen KT, Huang HF (1994). "Combined effects of chuling (Polyporus umbellatus) extract and mitomycin C on ...
Cancer present only in the bladder may be removed surgically via cystoscopy; an injection of the chemotherapeutic mitomycin C ...
1994). "p56/p53lyn tyrosine kinase activation in mammalian cells treated with mitomycin C.". Oncogene. 9 (10): 3005-11. PMID ...
PVOD has also been associated with several chemotherapy regimens such as bleomycin, BCNU, and mitomycin. Chloe Temtchine, ...
mitomycin (plural mitomycins). *(biochemistry) Any of a family of aziridine-containing natural products isolated from the ... Retrieved from "https://en.wiktionary.org/w/index.php?title=mitomycin&oldid=44962053" ...
Mitomycin: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving mitomycin,. *tell your doctor and pharmacist if you are allergic to mitomycin, any other medications, or any ... Mitomycin comes as a powder to be mixed with liquid and injected intravenously (into a vein) by a doctor or nurse in a medical ... Mitomycin is a type of antibiotic that is only used in cancer chemotherapy. It slows or stops the growth of cancer cells in ...
... has role antineoplastic agent (CHEBI:35610) mitomycin C (CHEBI:27504) is a mitomycin (CHEBI:25357) ... CHEBI:27504 - mitomycin C. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. ... via mitomycin ). bacterial metabolite Any prokaryotic metabolite produced during a metabolic reaction in bacteria. ... mitomycin C (CHEBI:27504) has role alkylating agent (CHEBI:22333) ...
Mitomycin Pyelocalyceal: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving mitomycin pyelocalyceal,. *tell your doctor and pharmacist if you are allergic to mitomycin, any other ... Mitomycin is in a class of medications called anthracenediones (anticancer antibiotics). Mitomycin pyelocalyceal treats cancer ... Mitomycin comes as a powder to be mixed with a gel solution and given through a catheter (a small flexible plastic tube) into ...
... injection contains the active ingredient mitomycin, which is a type of anticancer chemotherapy medicine ... Mitomycin C Kyowa. Mitomycin C Kyowa injection contains the active ingredient mitomycin, which is a type of anticancer ... Mitomycin works by stopping the cancer cells from growing and multiplying.. Mitomycin inserts itself into the strands of ... Mitomycin C Kyowa injection contains the active ingredient mitomycin, which is a type of anticancer chemotherapy medicine ...
A list of US medications equivalent to Mitomycin is available on the Drugs.com website. ... Mitomycin is a medicine available in a number of countries worldwide. ... Mitomycin. In the US, Mitomycin (mitomycin systemic) is a member of the drug class antibiotics/antineoplastics and is used to ... Mitomycin C Arrow. Actavis, New Zealand. *Mitomycin C Kyowa. Ebewe Pharma, Austria; Kyowa Hakko Kirin, China; Nordic Group, ...
Find out more about how it is given and possible side effects of mitomycin. ... Mitomycin is also known as Mitomycin C Kyowa®. It is used to treat many different types of cancer. ... What is mitomycin (Mitomycin C Kyowa®)?. Mitomycin (Mitomycin C Kyowa®) is a chemotherapy drug used to treat different cancers ... How mitomycin is given. You will be given mitomycin in the chemotherapy day unit or during a stay in hospital. A chemotherapy ...
When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to ... When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to ... is there anything like that for mitomycin tx? ...
... NSC365354 Mitomycin C analog
Advice and warnings for the use of Mitomycin ophthalmic (Mitosol) during pregnancy. FDA Pregnancy Category X - Not for use in ... Mitomycin ophthalmic Pregnancy and Breastfeeding Warnings. Mitomycin ophthalmic is also known as: Mitosol ... Mitomycin ophthalmic Breastfeeding Warnings. Use is not recommended and a decision should be made to discontinue breastfeeding ... Mitosol (mitoMYcin ophthalmic)." Mobius Therapeutics, St. Loius, MO. *United States National Library of Medicine "Toxnet. ...
Mitomycin (UNII: 50SG953SK6) (Mitomycin - UNII:50SG953SK6) Mitomycin. 0.2 mg in 1 mL. ... Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to ... Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to ... MITOSOL- mitomycin kit. To receive this label RSS feed. Copy the URL below and paste it into your RSS Reader application. https ...
Mitomycin (Mutamycin) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatment of ... Mutamycin is the trade name for mitomycin. MTC and Mitomycin-C are other names for mitomycin. In some cases, health care ... There is no pill form of mitomycin. *The amount of mitomycin that you will receive depends on many factors, including your ... There is a maximum lifetime dose of mitomycin. Your health care professional will monitor the amount of mitomycin you receive ...
Mitomycin sometimes causes a temporary loss of hair. After treatment has ended, normal hair growth should return. ...
Mitomycin is usually given together with certain other medicines. If you are using a combination of medicines, it is important ...
They include mitomycin A, mitomycin B, and mitomycin C. When the name mitomycin occurs alone, it usually refers to mitomycin C ... Mitomycin C is used as a medicine for treating various disorders associated with the growth and spread of cells. In general, ... Mitomycin C is used to treat symptoms of pancreatic and stomach cancer, and is under clinical research for its potential to ... "Mitomycin". Drugs.com. 2017. Retrieved 11 November 2017. Rustagi, T; Aslanian, H. R; Laine, L (2015). "Treatment of Refractory ...
Find patient medical information for Mitomycin Intravenous on WebMD including its uses, side effects and safety, interactions, ... mitomycin 20 mg intravenous solution. color. blue violet. shape. No data.. imprint. No data.. This medicine is a blue violet, ... mitomycin 40 mg intravenous solution. color. blue violet. shape. No data.. imprint. No data.. This medicine is a blue violet, ... mitomycin 40 mg intravenous solution. color. colorless. shape. No data.. imprint. No data.. This medicine is a colorless, clear ...
Mitomycin C (Ametycine, Mutamycin [MMC]; CAS No. 50-07-7), was studied. MMC, a documented animal teratogen, is an antibiotic ... To further characterize the Drosophila-based prescreen to detect developmental toxicants, Mitomycin C (Ametycine, Mutamycin [ ...
MITOMYCIN, 20MG, INJ.POWDER. Common uses. This medication is typically used as part of chemotherapy. ...
A MOLECULAR MECHANISM OF MITOMYCIN ACTION: LINKING OF COMPLEMENTARY DNA STRANDS Message Subject (Your Name) has sent you a ... A MOLECULAR MECHANISM OF MITOMYCIN ACTION: LINKING OF COMPLEMENTARY DNA STRANDS. V. N. Iyer and W. Szybalski ...
Mitomycins. Mitomycin. Antibiotics, Antineoplastic. Antineoplastic Agents. Alkylating Agents. Molecular Mechanisms of ... Mitomycin-c Application for PRK. The safety and scientific validity of this study is the responsibility of the study sponsor ... Mitomycin-c Application for Photorefractive Keratectomy. Resource links provided by the National Library of Medicine ... Drug: mitomycin-C. Placebo Comparator: BSS group One eye of each patient was randomly assigned to receive balanced salt ...
Mit-C information about active ingredients, pharmaceutical forms and doses, Mit-C indications, usages and related health products lists
Mitomycin C for glaucoma surgery. Surgical treatment of glaucoma is usually reserved for serious cases which cannot be ... Mitomycin C is a powerful agent which prevents scarring by inhibiting the multiplication of cells which produce scar tissue. ... The review found evidence that Mitomycin C reduces the risk of surgical failure in both high risk and primary surgery but no ... Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery. *Combined glaucoma and cataract surgery versus ...
... Timothy D. Lyon, Omar M. Ayyash, Matthew C ... "Bipolar Transurethral Incision of Bladder Neck Stenoses with Mitomycin C Injection," Advances in Urology, vol. 2015, Article ID ...
... Timothy D. Lyon, Omar M. Ayyash, Matthew C ... A. J. Vanni, L. N. Zinman, and J. C. Buckley, "Radial urethrotomy and intralesional mitomycin C for the management of recurrent ... B. Ferguson, S. D. Gray, and S. Thibeault, "Time and dose effects of mitomycin C on extracellular matrix fibroblasts and ... J. D. Redshaw, J. A. Broghammer, T. G. Smith et al., "Intralesional injection of mitomycin C at transurethral incision of ...
Mitomycin C in patients with gynecological malignancies.. [Laura Kahmann, Ulrich Beyer, Grit Mehlhorn, Falk C Thiel, Vratislav ... Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast ... Mitomycin, European Pharmacopoeia (EP) Reference Standard C15H18N4O5 ...
2001). Functional enhancement of CFTR expression by mitomycin C. Cellular Physiology and Biochemistry, 11(2), 93-98. ... We report that mitomycin C (MMC) elicits such a response by increasing CFTR mRNA and protein expression in T-84 and HT-29 cells ...
Mitomycin C Treated Normal Human Neonatal Dermal Fibroblasts, when recovered in complete fibroblast growth media, provide an ... Primary Dermal Fibroblast; Normal, Human, Neonatal, Mitomycin C Treated (HDFn) (ATCC® PCS-201-011™) Organism: Homo sapiens, ... Primary Dermal Fibroblast; Normal, Human, Neonatal, Mitomycin C Treated (HDFn) ATCC® PCS-201-011™ frozen 1 mL ... Primary neonatal fibroblasts have been treated with mitomycin C at passage #1 and will not replicate. Once the feeder cells ...
... Authors: H.A. Alhadrami ... Keywords: SOS-lux biosensors, salmonella assay, in vitro digestion, mutagenicity, bioluminescent bacteria, Mitomycin C ...
Drug: Mitomycin -C Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial ... Mitomycins. Mitomycin. Antibiotics, Antineoplastic. Antineoplastic Agents. Alkylating Agents. Molecular Mechanisms of ... Study of Mitomycin-C Application in Laryngotracheal Stenosis. This study is currently recruiting participants. See Contacts and ... Experimental: Mitomycin-C Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial ...
Slavisa T, et al. A Definitive IMRT-SIB with concomitant chemotherapy for synchronous locally advanced anal canal cancer and prostate cancer. Case Reports in Oncological Medicine 2018: Jan 2018. Available from: URL: http://doi.org/10.1155/2018/6101759 - Austria ...
  • Mitomycin may cause hemolytic uremic syndrome (a potentially life-threatening condition that involves injury to red blood cells, causing anemia and kidney problems). (medlineplus.gov)
  • Hemolytic-uremic syndrome is an uncommon, but serious side effect that may be caused by treatment with mitomycin. (unm.edu)
  • We describe a patient with the adult hemolytic-uremic syndrome due to mitomycin who was successfully treated with intense plasma exchange therapy and corticosteroid therapy. (deepdyve.com)
  • 9. Hardin E, Lucas VS, Prora A, et al: Hemolytic-uremic syndrome during therapy with mitomycin C plus 5-fluorouracil, abstracted. (deepdyve.com)
  • 20. Pavy MD, Wiley EL, Abeloff MD: Hemolytic-uremic syndrome associated with mitomycin therapy. (deepdyve.com)
  • Mitomycin Cinduced hemolytic uremic syndrome. (semanticscholar.org)
  • Mutamycin is the trade name for mitomycin. (chemocare.com)
  • In some cases, health care professionals may use the trade name mutamycin or other names MTC or Mitomycin-C when referring to the generic drug name mitomycin. (chemocare.com)
  • The side effects of mitomycin and their severity depend on how much of the drug is given, and how it is given. (chemocare.com)
  • The genetic effects of mitomycin C in Drosophila melanogaster. (wikipedia.org)
  • How long does it take for the effects of mitomycin to kick in? (healthtap.com)
  • Common side effects of mitomycin for injection include fever, loss of appetite, nausea, and vomiting. (medicineshoppe.com)
  • To determine the effects of mitomycin C (MMC) on the expression of chymase and mast cells in the conjunctival scar after trabeculectomy. (molvis.org)
  • Your doctor will order certain tests before and during your treatment to see if it is safe for you to receive mitomycin injection and to check your body's response to mitomycin injection. (medlineplus.gov)
  • Mitomycin injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (medlineplus.gov)
  • It is important for you to tell your doctor how you are feeling during your treatment with mitomycin injection. (medlineplus.gov)
  • tell your doctor and pharmacist if you are allergic to mitomycin, any other medications, or any of the ingredients in mitomycin injection. (medlineplus.gov)
  • Your doctor may not want you to receive mitomycin injection. (medlineplus.gov)
  • Mitomycin C Kyowa injection contains the active ingredient mitomycin, which is a type of anticancer chemotherapy medicine called a cytotoxic antibiotic. (netdoctor.co.uk)
  • Mitomycin may also be given by injection into an artery that delivers the blood supply to a particular organ, for example to treat cancer of the liver. (netdoctor.co.uk)
  • Your nurse will give you mitomycin as an injection into your cannula or line, with a drip (infusion) to flush it through. (macmillan.org.uk)
  • when reconstituted with Sterile Water for Injection, the solution contains 0.2 mg/mL mitomycin. (nih.gov)
  • Intralesional injection of mitomycin C at transurethral incision of bladder neck contracture may offer limited benefit: TURNS Study Group," Journal of Urology , vol. 193, no. 2, pp. 587-592, 2015. (hindawi.com)
  • They include mitomycin A, mitomycin B, and mitomycin C. When the name mitomycin occurs alone, it usually refers to mitomycin C, its international nonproprietary name. (wikipedia.org)
  • Mitomycin is in a class of medications called anthracenediones (anticancer antibiotics). (medlineplus.gov)
  • In the US, Mitomycin (mitomycin systemic) is a member of the drug class antibiotics/antineoplastics and is used to treat Bladder Cancer , Pancreatic Cancer and Stomach Cancer . (drugs.com)
  • Although other adjuvant treatments such as steroids and antibiotics have been investigated in LTS, much attention in recent years has turned to the use of topical mitomycin-C (MMC). (clinicaltrials.gov)
  • Mitomycin belongs to a class of agents called antitumor antibiotics. (unm.edu)
  • DNA adduct formation by enzyme-activated antibiotics, mitomycin C (MMC) or porfiromycin (PFM), at pH 7.6 or pH 6.0 under anaerobic conditions was analyzed by a 32P-postlabeling method. (aspetjournals.org)
  • The Mitomycin Antibiotics. (wikipedia.org)
  • Phase III Study of Concurrent versus Sequential Thoracic Radiotherapy in Combination with Mitomycin, Vindesine, and Cisplatin in Unresectable Stage. (oncolink.org)
  • Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without ma. (oncolink.org)
  • Putative defective repair of oxidative damage ( imp2′ Δ strain) also resulted in sensitivity to platinum and oxaliplatin, but not to mitomycin C. Surprisingly in light of their different profiles of clinical activity, cisplatin and oxaliplatin have very similar sensitivity profiles. (aacrjournals.org)
  • Finally, we identified three novel genes ( PSY1-3 , "platinum sensitivity") that, when deleted, demonstrate sensitivity to cisplatin and oxaliplatin, but not to mitomycin C. Our results emphasize the importance of multiple DNA repair pathways responsible for normal cellular resistance to all three of the agents. (aacrjournals.org)
  • Also, the similarity of the sensitivity profiles of the platinum agents with that of the known DNA interstrand cross-linking agent mitomycin C, and the importance of the gene PSO2 known to be involved in DNA interstrand cross-link repair strongly suggests that interstrand cross-links are important toxic lesions for cisplatin and oxaliplatin, at least in yeast. (aacrjournals.org)
  • The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. (wikipedia.org)
  • Mitomycin C is an antibiotic derived from Streptomyces caespitosus and is generally classified as a DNA alkylating agent. (pubmedcentralcanada.ca)
  • Mitomycin C (MMC), an antitumor agent isolated from Streptomyces cultures, is used in chemotherapy ( 30 ). (asm.org)
  • Mitomycin C is produced by a strain of actinomyces, Streptomyces caespitosus . (agscientific.com)
  • Safety and feasibility of early single dose mitomycin-C bladder instillation post robot-assisted radical nephroureterectomy. (urotoday.com)
  • To assess the safety and feasibility of early single dose mitomycin-C (MMC) bladder instillation following robot-assisted radical nephroureterectomy (RANU) at a tertiary kidney cancer centre. (urotoday.com)
  • Radical nephroureterectomy with bladder cuff excision and subsequent mitomycin-C (MMC) bladder instillation to reduce recurrence risk is the gold standard for high risk upper urinary tract urothelial carcinoma (UUTUC). (urotoday.com)
  • The instillation of the mitomycin c was written in after I had signed the form, and was approved by a different urologist other than my own. (bladdercancersupport.org)
  • There is good quality evidence that instillation of a chemotherapeutic agent such as mitomycin into the bladder within twenty-four hours of an initial transurethral bladder tumour resection reduces the rate of recurrences and prolongs recurrence-free intervals in patients with non-muscle invasive bladder cancer. (urotoday.com)
  • Based on this knowledge, we trained stakeholders in improved prescription practices as well as on-table mitomycin instillation. (urotoday.com)
  • Lung parenchyma disease following instillation of mitomycin C in the bladder]. (pneumotox.com)
  • Your doctor will probably tell you not to receive mitomycin pyelocalyceal. (medlineplus.gov)
  • Patients then receive mitomycin intraperitoneally (IP) over 23 hours on day 1 and fluorouracil IP over 24 hours on days 2-5. (knowcancer.com)
  • This is a rare event seen in less than 2 % of patients treated with mitomycin, it can occur at any time but usually seen after several cycles of therapy. (chemocare.com)
  • To evaluate the safety and efficacy of 5 seconds mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for patients with low myopia. (clinicaltrials.gov)
  • Mitomycin C in patients with gynecological malignancies. (sigmaaldrich.com)
  • Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast carcinoma. (sigmaaldrich.com)
  • This is a randomized, prospective, double-blind, placebo-controlled clinical trial of the use of mitomycin-C topical application as an adjunctive treatment in the endoscopic surgical treatment of patients with laryngotracheal stenosis. (clinicaltrials.gov)
  • This study will determine if the addition of topical mitomycin-C increases the duration of time to repeat surgery in patients undergoing endoscopic surgical treatment for laryngotracheal stenosis. (clinicaltrials.gov)
  • The study will determine if the addition of topical mitomycin-C will increase the duration of symptom improvement in patients undergoing endoscopic surgical treatment for laryngotracheal stenosis. (clinicaltrials.gov)
  • The study will determine if the addition of topical mitomycin-C will increase the duration of PIF improvement in patients undergoing endoscopic surgical treatment for laryngotracheal stenosis. (clinicaltrials.gov)
  • In the past 2 years we have seen two patients who died with unexplained severe interstitial pneumonitis after receiving mitomycin chemotherapy. (annals.org)
  • Group 1 received a single dosage of topical 0.02% mitomycin C for 5 min at the completion of the surgery whereas group 2 underwent the same procedure but received NaCl 0.9% instead of mitomycin C. Patients were followed from 6 to 15 months in a masked manner. (nih.gov)
  • Four patients with corneal scarring and high corneal astigmatism related to previous pterygium surgery underwent diamond burr superficial keratectomy with application of mitomycin C. Anterior segment photography and corneal topographic analysis were obtained preoperatively and postoperatively in all patients. (dovepress.com)
  • Diamond burr superficial keratectomy with application of mitomycin C is a potentially effective and simple procedure for treating patients with corneal scarring and high corneal astigmatism secondary to previous pterygium surgery. (dovepress.com)
  • Patients will usually have scheduled meetings with their healthcare provider while they are being treated with mitomycin. (unm.edu)
  • Patients will also have their lung function monitored, as problems of the lung may result due to treatment with mitomycin. (unm.edu)
  • In addition, patients may experience an allergic-type reaction to mitomycin, although this is uncommon. (unm.edu)
  • What are the common (occur in 30% or more of patients) side effects of treatment with mitomycin? (unm.edu)
  • What are the less common (occur in 10% to 29% of patients) side effects of treatment with mitomycin? (unm.edu)
  • An open prospective analysis of 20 cases of corneal conjunctival intraepithelial neoplasia with recurrent disease (17 patients) or refusing surgery (three patients) were treated with topical mitomycin C. Treatment was with mitomycin C eye drops, either 0.02% or 0.04%, four times daily for 1 week followed by a week off the cycle then repeated for a second week. (nih.gov)
  • They compared a group of these patients with patients receiving only mitomycin-C and found a significant improvement in survival in the patients receiving combined therapy. (medscape.com)
  • Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients. (medscape.com)
  • OBJECTIVES: I. Compare the efficacy of adjuvant systemic fluorouracil with intraperitoneal mitomycin vs systemic fluorouracil alone in terms of survival in patients with peritoneal cancer originating from the colorectum. (knowcancer.com)
  • Determine the effectiveness of laparoscopic hyperthermic perfusion of mitomycin C in preventing relapse at 4 weeks post-treatment in patients with malignant ascites. (knowcancer.com)
  • We conducted a multicenter phase II study to assess the toxicity and efficacy of a combination of mitomycin C (MMC) and capecitabine in pretreated patients with metastatic or locally advanced gastric cancer. (springer.com)
  • Bamias A, Papamichael D, Syrigos K, Pavlidis N (2003) Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. (springer.com)
  • Chen JS, Lin YC, Liau CT, Wang CH, Liaw CC (2003) Mitomycin C (MMC) with weekly 24-hour infusions of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer. (springer.com)
  • Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N (2005) Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. (springer.com)
  • The authors' conclusions concerning safety must be limited by three specific factors: most patients were treated with only one concentration of mitomycin (0.04%) topically administered four times a day using a "week on and week off regimen," the "treatment was only commenced after complete epithelial healing was achieved," and that "punctal plugs were not used during MMC treatment in any of our cases. (bmj.com)
  • Personnel were trained by certified chemotherapy nurses in the safe delivery of intravesical mitomycin instillations both by ex vivo instruction and supervised practice on patients. (urotoday.com)
  • A prospective randomized trial comparing streptozotocin, mitomycin C, and 5-FU (SMF) with mitomycin C and 5-FU (MF) in patients with advanced pancreatic cancer was performed. (uni-bonn.de)
  • It is not yet known whether combining mitomycin or porfiromycin with radiation therapy is more effective in treating patients with head and neck cancer. (clinicalconnection.com)
  • PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus either mitomycin or porfiromycin in treating patients with head and neck cancer. (clinicalconnection.com)
  • Patients receiving mitomycin should have their conditions monitored closely for acute renal failure, thrombocytopenia, and hemolytic anemia. (deepdyve.com)
  • Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (rochester.edu)
  • Mitomycin is also sometimes used intravesically (infused directly into the bladder) to treat bladder cancer. (medlineplus.gov)
  • For treating bladder cancer mitomycin may be administered directly into the bladder via a catheter. (netdoctor.co.uk)
  • mitomycin given directly into the bladder to treat non-invasive bladder cancer. (macmillan.org.uk)
  • Mitomycin is usually injected into a vein but can also be instilled intravesically (into the bladder) for treatment of bladder cancer. (medbroadcast.com)
  • Usually BCG is the treatment of choice for high grade or recurrent bladder cancer and mitomycin is used only when a patient cannot tolerate BCG. (bladdercancersupport.org)
  • I'm about to have my 6th of 6 mitomycin treatment for bladder cancer. (healthtap.com)
  • So please, file a complaint so the Department of Justice can intervene on our behalf, and stop the off label use of Mitomycin C for early stages of bladder cancer. (bladdercancersupport.org)
  • Mitomycin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. (chemocare.com)
  • Before receiving each mitomycin dose, your doctor may tell you to take sodium bicarbonate. (medlineplus.gov)
  • Do not breastfeed while you are receiving mitomycin pyelocalyceal and for 1 week after your final dose. (medlineplus.gov)
  • you should know that mitomycin pyelocalyceal may temporarily change the color of your urine to a blue-green color after you receive a dose. (medlineplus.gov)
  • If you miss an appointment to receive a dose of mitomycin pyelocalyceal, call your doctor as soon as possible to reschedule. (medlineplus.gov)
  • There is a maximum lifetime dose of mitomycin. (chemocare.com)
  • The first case was that of a 53-year-old man with adenocarcinoma of the pancreas who received weekly mitomycin, 5-fluorouracil, and cytosine arabinoside during an 18-week period for a total mitomycin dose of 50 mg. (annals.org)
  • The recommended dose and dosing schedule of mitomycin varies according to the specific condition being treated, the response to therapy, and other medications or treatments being used. (medbroadcast.com)
  • Mitomycin may be administered into a vein (intravenous) and the dose depends on several factors, including the condition being treated, the size of the patient, the particular treatment regimen being used, and the overall health of the patient. (unm.edu)
  • The antifibrotic agent delivery system enables a precise dose of mitomycin C to be delivered to ophthalmic surgeons for use in procedures without any change to their current technique, according to the company, which is awaiting decisions from the FDA regarding refractive and corneal indications for the solution. (ophthalmologytimes.com)
  • To evaluate the efficacy of topical mitomycin C as a treatment of corneal conjunctival intraepithelial neoplasia. (nih.gov)
  • What is the efficacy of combined intravesical mitomycin-C and local microwave-induced hyperthermia for the treatment of bladder carcinoma in situ? (medscape.com)
  • To compare the efficacy and complications of conjunctival limbal autograft (CLAU) and amniotic membrane transplantation (AMT) vsintraoperative mitomycin C (MMC) and AMT for treatment of recurrent pterygium. (unboundmedicine.com)
  • OBJECTIVES: I. Compare the efficacy of mitomycin vs. porfiromycin as an adjunct to radiotherapy for the treatment of epidermoid carcinomas of the head and neck. (clinicalconnection.com)
  • This study compared the efficacy and safety of suberoylanilide hydroxamic acid (SAHA) and mitomycin C (MMC) up to 4 months in the prevention of corneal haze induced by photorefractive keratectomy (PRK) in rabbits in vivo. (healio.com)
  • In this study, we compared in vivo long-term safety and efficacy of SAHA with mitomycin C (MMC) for preventing corneal haze after PRK using an established in vivo rabbit model and no-drug treatment control. (healio.com)
  • A Phase III comparison of CAC versus standard treatment using streptozotocin, mitomycin, and 5-fluorouracil (SMF) was performed. (uni-bonn.de)
  • 21. Gulati SC, Sordillo P, Kempin S, et al: Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. (deepdyve.com)
  • Mitomycin has been associated with microangiopathic hemolytic anemia and renal failure. (deepdyve.com)
  • Three cases of renal failure associated with microangiopathic hemolytic anemia after mitomycin C therapy]. (semanticscholar.org)
  • Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation. (nih.gov)
  • Mitomycin C is used to treat symptoms of pancreatic and stomach cancer, and is under clinical research for its potential to treat gastrointestinal strictures, wound healing from glaucoma surgery, corneal excimer laser surgery and endoscopic dacryocystorhinostomy. (wikipedia.org)
  • The purpose of this paper is to report the successful treatment of corneal scarring and high corneal astigmatism secondary to previous pterygium surgery with diamond burr superficial keratectomy using mitomycin C. (dovepress.com)
  • Mitomycin C is effective in inducing regression of corneal conjunctival intraepithelial neoplasia. (nih.gov)
  • This brief review examines both basic science and clinical studies to evaluate the potential impact on the health of the corneal endothelium of mitomycin C (MMC) usage during photorefractive keratectomy (PRK). (pubmedcentralcanada.ca)
  • Mitomycin C (MMC) was proposed to be an effective modulator of the wound healing response after corneal stromal ablation as early as 1991. (pubmedcentralcanada.ca)
  • To investigate how mitomycin C (MMC) modulates hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) secretions in human corneal fibroblasts and regulates human corneal epithelial (HCE) cell migration. (arvojournals.org)
  • Therefore, in this study, we hypothesized that emodin could enhance the effects of the antitumor antibiotic mitomycin C (MMC)-mediated cytotoxicity by decreasing the expression of Rad51 and the phosphorylation of ERK1/2. (aspetjournals.org)
  • Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA. (nih.gov)
  • A new covalent mitomycin C-DNA adduct (4) was isolated from DNA exposed to reductively activated mitomycin C (MC) in vitro. (nih.gov)
  • Tomasz et al (1987) Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. (tocris.com)
  • Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes. (clinicaltrials.gov)
  • We studied the recurrence rate of pterygium after administration of a single dosage of topical mitomycin C at the completion of pterygium surgery. (nih.gov)
  • This study indicates the possible advantage of administration of a single dosage of 0.02% mitomycin C for postoperative prevention of recurrence of pterygium. (nih.gov)
  • Mitomycin may cause nausea and vomiting, but it is important to keep using this medication even if you feel ill. (medbroadcast.com)
  • Mitomycin is a chemotherapy medication that is used for the treatment of stomach & pancreatic cancer . (healthtap.com)
  • Two years later, nonpenetrating glaucoma surgery with mitomycin-C (MMC) 0.02% was performed for uncontrolled glaucoma. (cun.es)
  • Mitosol (mitoMYcin ophthalmic). (drugs.com)
  • Mobius Therapeutics has received final approval from the FDA for use of its mitomycin C ophthalmic solution (Mitosol) in glaucoma surgery. (ophthalmologytimes.com)
  • Mitomycin can be given in combination with other cancer drugs and with radiotherapy . (macmillan.org.uk)
  • I am also sorry about your reaction to mitomycin, I had it instilled in me four weeks ago after my TURBT, and I too have developed cystitis as a result, but despite that, it is standard protocol for cancer surgery in the bladder and I am glad the urologist did it to protect against residual cancer cells. (bladdercancersupport.org)
  • Treatment of recurrent pterygium associated with symblepharon usually involves the use of tissue grafting and/or the intraoperative application of mitomycin C (MMC). (dovepress.com)
  • Prospective study of the effect of topical application of Mitomycin C in refractory pediatric. (deepdyve.com)
  • The review found evidence that Mitomycin C reduces the risk of surgical failure in both high risk and primary surgery but no evidence on combined cataract and glaucoma surgery. (cochrane.org)
  • Mitomycin can also be used during glaucoma surgery. (medicineshoppe.com)
  • Mitomycin solution is used during glaucoma surgery. (medicineshoppe.com)
  • Serious side effects have been reported with mitomycin solution for glaucoma surgery. (medicineshoppe.com)
  • New research about staged buccal mucosa graft urethroplasty and a study examining urethrotomy with mitomycin C for recurrent bladder neck contractures are among the key research in trauma/reconstruction being presented at the 2014 AUA annual meeting. (urologytimes.com)
  • Intermediate-term outcomes in the management of recurrent bladder neck contractures with urethrotomy and mitomycin C. (urologytimes.com)
  • Long story short after multiple cystoscopy and removal of many pillary tumors this January the dr want to do a TUR and start mitomycin treatment once a month. (bladdercancersupport.org)
  • Will start mitomycin c. (healthtap.com)
  • The dr told me that treatment once a month would be enought because the tumors looked low gràde but then the pathology report came back and we received a phone call saying that my husband has to start weekly mitomycin treatments. (bladdercancersupport.org)
  • Colombo et al have reported beneficial results using a combination of intravesical mitomycin-C and local microwave-induced hyperthermia. (medscape.com)
  • We found a similar lacuna in the frequency of use of intravesical mitomycin in our hospitals. (urotoday.com)
  • Therefore, to improve compliance with the use of intravesical chemotherapy, we devised a care bundle to help urologists become complaint with intravesical mitomycin. (urotoday.com)
  • Subsequent audits showed much-improved compliance with the use of intravesical mitomycin by following the care-bundle. (urotoday.com)
  • We make a case that a care bundle approach helps teams achieve compliance with intravesical mitomycin use where it is indicated. (urotoday.com)
  • Intravesical mitomycin-C-induced interstitial pneumonia. (pneumotox.com)
  • Mitomycin is used in combination with other medications to treat cancer of the stomach or pancreas that has spread to other parts of the body and has not improved or worsened after treatment with other medications, surgery, or radiation therapy. (medlineplus.gov)
  • You should not breast-feed during your treatment with mitomycin. (medlineplus.gov)
  • If you are responding to mitomycin pyelocalyceal 3 months after beginning treatment, it may continue to be given once a month for up to 11 months. (medlineplus.gov)
  • You should not become pregnant during your treatment with mitomycin pyelocalyceal. (medlineplus.gov)
  • If you or your partner becomes pregnant during your treatment with mitomycin pyelocalyceal, call your doctor immediately. (medlineplus.gov)
  • Your health care professional will monitor the amount of mitomycin you receive as well as your lung function during treatment. (chemocare.com)
  • We hypothesize that the use of mitomycin-C improves patient outcome in the endoscopic surgical treatment of laryngotracheal stenosis. (clinicaltrials.gov)
  • The purpose of this study is to determine the effectiveness and safety of mitomycin C in the treatment of primary sclerosing cholangitis (PSC). (clinicaltrials.gov)
  • Mitomycin is FDA approved for the treatment of advanced stomach and pancreatic cancer in combination with other agents. (unm.edu)
  • Treatment with mitomycin-C (0.4mg/mL) increased the apoptosis of HTCFs, which was characterized as fragmentation of nucleic acid and genomic DNA, chromatin condensation, and increase in sub-G(0)/G(1) fraction of cell cycle. (arvojournals.org)
  • Each vial of Mitosol ® contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. (nih.gov)
  • Who should not take Mitomycin Vial? (webmd.com)
  • What conditions does Mitomycin Vial treat? (webmd.com)
  • List Mitomycin Vial side effects by likelihood and severity. (webmd.com)
  • Each vial contains mitomycin 5 mg as sterile lyophilized powder. (medbroadcast.com)
  • Mitomycin (Mitomycin C Kyowa ® ) is a chemotherapy drug used to treat different cancers including breast, bladder, gullet (oesophagus), stomach, pancreas, lung, anal and liver cancers. (macmillan.org.uk)
  • Like all chemotherapy drugs, mitomycin can cause side effects. (macmillan.org.uk)
  • This protocol describes an efficient and convenient analytical process of sample extraction and simultaneous determination of multiple drugs, doxorubicin (DOX), mitomycin C (MMC) and a cardio-toxic DOX metabolite, doxorubicinol (DOXol), in the biological samples from a preclinical breast tumor model treated with nanoparticle formulations of synergistic drug combination. (jove.com)
  • Our previous studies have shown that the combination of two anticancer drugs, doxorubicin (DOX) and mitomycin C (MMC), produced a synergistic effect against both murine and human breast cancer cells in vitro . (jove.com)
  • Buzdar AV, Legha SS, Tashima CK, et al: Adriamycin and mitomycin C: Possible synergistic cardiotoxicity. (deepdyve.com)
  • 14 instillations of Mitomycin C has help me to be cancer free for the last 2 years. (bladdercancersupport.org)
  • Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: A case report. (pneumotox.com)
  • To the editor: Orwoll and others (1) have reported in the September issue on the association of mitomycin with interstitial pneumonia. (annals.org)
  • Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (linkedlifedata.com)
  • Godfrey TE, Wilbur DW: Clinical experience with mitomycin C in large infrequent doses. (deepdyve.com)
  • Mitomycin may cause side effects. (medlineplus.gov)
  • The dr just told me that he thinks that the mitomycin would do the job, and that once a week would be enough because the side effects are worse with weekly than with the monthly treatments. (bladdercancersupport.org)
  • What side effects can Mitomycin cause? (nni.com.sg)
  • Horse or sore throat and fatigue can all be Mitomycin side effects. (healthtap.com)
  • This is not a complete list of mitomycin side effects. (medicineshoppe.com)
  • 4 In this issue of BJO (p 819), two Australians, Khong and Muecke, report on a retrospective study of the ocular side effects of topical mitomycin chemotherapy (TMC) on 100 eyes treated for malignant ocular surface neoplasias. (bmj.com)
  • MITOMYCIN (mye toe MYE sin) is a chemotherapy drug. (ahealthyme.com)
  • This is not a complete list of mitomycin drug interactions. (medicineshoppe.com)
  • The effect of chemotherapy drug Mitomycin C (MMC) in combination with recombinant adeno-associated virus II (rAAV2) in cancer therapy was investigated, and the mechanism of MMC affecting rAAV2's bioactivity was also studied. (mdpi.com)
  • Mitomycin C (MC) is a potent antitumor drug. (pubmedcentralcanada.ca)
  • There were no long-term complications on discontinuing mitomycin C. (nih.gov)
  • Developmental toxicity of mitomycin C in Drosophila melanogaster. (cdc.gov)
  • 5. Liu K, Mittleman A, Sproul EE, et al: Renal toxicity in man treated with mitomycin C. Cancer 1971;28:1314-1320.Crossref 6. (deepdyve.com)
  • Mitomycin comes as a powder to be mixed with liquid and injected intravenously (into a vein) by a doctor or nurse in a medical facility. (medlineplus.gov)
  • Mitomycin is given into a vein. (macmillan.org.uk)
  • If mitomycin leaks from the vein into which it is being administered, it may cause serious damage to the surrounding tissue. (unm.edu)
  • Mitomycin is also available in an injectable form to be given directly into a vein (IV) by a healthcare professional. (medicineshoppe.com)
  • Mammalian Cells treated with Mitomycin C (0.4 mg/mL for 5 min) can undergo apoptosis through upregulation of Bad, Fas, FasL and phosphorylated p53 along with activation of caspase-3, caspase-8, and caspase-9 activating both the intrinsic and extrinsic pathway for apoptosis. (scbt.com)
  • Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. (aacrjournals.org)
  • Previous studies have shown that the PKC-specific inhibitor safingol significantly enhances the induction of apoptosis by mitomycin-C (MMC) in gastric cancer cells. (aacrjournals.org)
  • Mitomycin C (4% in NaCl) is a DNA crosslinking agent which inhibits DNA synthesis and causes apoptosis via a p53-dependent pathway. (agscientific.com)
  • Mitomycin may be used on its own or in combination with other anticancer medicines. (netdoctor.co.uk)
  • Is mitomycin-n, an injectible medicine, a possible alternative to radiation therapy for cheek carcinoma? (healthtap.com)
  • The use of topical mitomycin C (MMC) has gained popularity in the management of ocular surface neoplasia. (eurekamag.com)
  • Enhancing effect of tetrandrine on sister-chromatid exchanges induced by mitomycin C and cigarette-smoke condensate in mammalian cells. (cdc.gov)